Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vaxart, Inc.
A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
While AstraZeneca’s adenovirus candidate is expected to use Operation Warp Speed’s platform, its start date remains cloaked; the Janssen and Novavax candidates are expected to enter Phase III in September and October, respectively.
- Drug Delivery
- Other Names / Subsidiaries
- Aviragen Therapeutics, Inc. (Anaconda Pharma SAS
- Biota Holdings Limited
- Biota Pharmaceuticals, Inc.
- Nabi Biopharmaceuticals)